Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Eyevensys Appoints Dr Ivan Cohen-Tanugi as CEO

Published: Tuesday, March 26, 2013
Last Updated: Tuesday, March 26, 2013
Bookmark and Share
Dr Ivan Cohen-Tanugi, with over 20 years’ experience in the international pharmaceutical industry, will prepare Eyevensys to launch clinical trials for the company’s non-viral gene therapy processes in two ophthalmic indications.

Eyevensys has announced the appointment of Dr Ivan Cohen-Tanugi as CEO.

Having worked for Sanofi, Amgen International, Roche Pharma and Teva Pharmaceuticals, Dr Cohen-Tanugi first plans to conclude Eyevensys’ preclinical tests over the next 12 months. The first human tests are planned within 18 months.

The Eyevensys process is an electrotransfer of plasmids in the ciliary muscle of the eye.

The Eyevensys team is one of a small group that has reached an advanced stage of development of the process using a non-viral approach.

This treatment is less invasive than current treatments. It allows for injections to be administered from either once a fortnight or monthly to once every six months.

This reduces the dose of drugs and proteins, consequently reducing side effects.

The first preclinical results from animal subjects show therapeutic protein expressions for up to nine months. These results have been the focus of articles published in reputed scientific journals.

“I am delighted to have been given the responsibility of leading Eyevensys through to the next stages of its development,” said Dr Ivan Cohen-Tanugi , CEO at Eyevensys.

Dr Cohen-Tanugi continued, “Eyevensys is backed by stable and trusted investors who are very involved in the business’ development. A new financing round is planned for this year. We hope to sign up new stakeholders, notably on an international level, to diversify our support and proceed up to Phase II.”

“Ivan Cohen-Tanugi’s extensive experience in the pharmaceutical and biotechnological fields will contribute to Eyevensys’ ability to move at a faster pace and proceed to the clinical phase in the best possible circumstances,” said professor Francine Behar-Cohen, Eyevensys’s founder and scientific advisor. “Our key goal is to discover proofs of concept for the electrotransfer process in humans.”

The company targets two main indications, where medical needs are currently urgent and unmet:
• Uveitis, an orphan disease, is an inflammation of the uvea (iris, ciliary body and/or choroid). It causes 10 per cent of cases of blindness in Western countries.

• Age-related Macular Degeneration (AMD) is a disease caused by a gradual degeneration of the macula, the central part of the retina, which can appear from age 50 and more frequently from age 65. It causes a significant weakening of visual capabilities, but does not destroy them.

The exact causes of this condition are unknown. No cure has yet been found. Existing treatments can only slow its progression. As much as 12 per cent of the population between ages 65 and 75 have AMD. It is the leading cause of non-correctable blindness in the western world. Due to population aging, its prevalence may increase by nearly 50 per cent by 2020. Worldwide, an estimated 25 million people are affected.

Dr Cohen-Tanugi, aged 51, has more than 20 years of experience in the international pharmaceutical and biotechnological industry. Before joining Eyevensys, he was vice president and general manager of the Biologics and Specialty unit at Teva Pharmaceuticals in the USA.

He has considerable experience in biologics and the pharmaceutical industry on an international level, notably in the fields of sales and marketing, global product launches, R&D team leadership and financing.

He worked in Switzerland for many years for Roche Pharma, then for Amgen International and finally for Teva Pharmaceuticals. Cohen-Tanugi started his career at Sanofi, where he held various positions in France and the USA. He is trained as a doctor and also holds an MBA from the HEC Business School.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Eyevensys Announces an Equity Investment by Boehringer Ingelheim Venture Fund
Dr Michel Pairet, Boehringer Ingelheim's head of non-clinical research and development, joins Eyevensys’ board of directors.
Thursday, April 11, 2013
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
BGI Sequences Gingko Tree, Revealing Large, Highly Repetitive Genome
Researchers at BGI have sequenced the more than 10-gigabase ginkgo genome to find a high number of repetitive sequences as well as a number of gene clusters that appear to be involved in defense mechanisms.
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
Accelerating the Detection of Foodborne Bacterial Outbreaks
The speed of diagnosis of foodborne bacterial outbreaks could be improved by a new technique developed by researchers at the Georgia Institute of Technology.
Making Personalized Medicine a Reality
Groundbreaking technique developed at McMaster University is helping to pave the way for advances in personalized medicine.
Scientists Identify Unique Genomic Features in Testicular Cancer
The findings may shed light on factors in other cancers that influence their sensitivity to chemotherapy.
Top 10 Life Science Innovations of 2016
2016 has seen the release of some truly innovative products. To help you digest these developments, The Scientist have listed their top picks for the year.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!